CONCORD BIOTECH — THE FERMENTATION API SPECIALIST 🧬

CONCORDBIO Not every pharma opportunity is about making finished medicines. Some of the most important businesses manufacture the ingredients that go into them. That's where Concord Biotech operates. The company specialises in fermentation-based APIs — complex drug ingredients produced using microorganisms. Its portfolio includes immunosuppressants, oncology and anti-infective products, with customers across India and international markets. This is a specialised segment where technical expertise, manufacturing consistency and regulatory approvals can create meaningful entry barriers. And Q2 FY27 delivered healthy revenue growth. Consolidated revenue from operations reached ₹309.1 crore, up 25.1% YoY. H1 FY27 revenue stood at ₹566.6 crore, growing 25.6%. But profitability tells a more nuanced story. Q2 consolidated PAT increased 10.3% to ₹69.6 crore, while H1 PAT grew 18.8% to ₹127.3 crore. Revenue is growing considerably faster than profit, making margin performance an important metric to monitor. The opportunity lies in three areas: Specialised APIs: Fermentation technology and complex manufacturing capabilities. Global markets: Export opportunities and diversified pharmaceutical customers. Capacity and product expansion: Scaling existing products while developing new molecules and applications. The business flywheel: Technical expertise → Regulatory approvals → Customer relationships → Repeat orders → Capacity utilisation → Earnings growth. However, investors should not overlook the risks. Margin pressure, raw-material costs, regulatory compliance, customer concentration, export-market exposure and capacity utilisation can all influence earnings. The latest quarter also shows why revenue growth alone is not enough: operating profitability needs to keep pace with sales. Concord is positioned in a specialised corner of the pharmaceutical value chain.